HC Wainwright & Co. Maintains Buy on Purple Biotech, Lowers Price Target to $17
HC Wainwright & Co. analyst Emily Bodnar maintains Purple Biotech (NASDAQ:PPBT) with a Buy and lowers the price target from $30 to $17.
Read original at benzingaStocks · News reference
CORRECTION: Purple Biotech Q2 EPS $(0.41) Beats $(0.98) Estimate
Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.98) by 58.16 percent. This is a 89.75 percent increase over losses of $(4.00) per share from
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 7, 2026, 1:24 PM
- Checked
- Aug 7, 2026, 1:24 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Purple Biotech Q2 EPS $(0.35) Beats $(0.98) Estimate
Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.98) by 64.29 percent. This is a 91.25 percent increase over losses of $(4.00) per share from
Read original at benzingaPPBT stock has given up its prior gain. Purple Biotech shares were trading higher after the company announced the presentation of new preclinical data from its lead CAPTN-3 program, IM1240, at EACR 2026 Annual Congress.
Read original at benzinga